The increasing prevalence of colorectal cancer across the globe, coupled with a growing aging population, is driving the demand for colorectal cancer therapeutics. Moreover, advancements in technology, such as precision medicine and targeted therapies, are providing new treatment options and driving market growth. Additionally, the rising healthcare expenditure and improving access to healthcare services are expected to boost the market further.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Drug Class |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Amgen Inc, Bayer AG, Bristol-Myers Squibb Company, Lilly, Merck & co.,, F. Hoffmann-La Roche, Sanofi |
The high cost of colorectal cancer therapeutics, particularly novel targeted therapies, poses a major restraint to market growth. This can limit access to these treatments for a significant portion of the population, especially in developing countries. Furthermore, regulatory challenges and stringent approval processes for new therapies can also hamper market expansion, delaying the introduction of potentially effective treatments to patients in need.